NeoStem Selected to Present Panel Discussion on Stem Cell Therapy at New York Biotechnology Association 2010 Annual Meeting
NEW YORK, April 15 /PRNewswire-Asia-FirstCall/ -- NeoStem, Inc. (NYSE Amex: NBS) (“NeoStem” or the “Company”), an international biopharmaceutical company with operations in the U.S. and China, announced that it has been selected to present a panel discussion at the New York Biotechnology Associa...
New Adult Stem Cell Collection Center in Austin to Open April 15, 2010 and Begin Collections
NEW YORK, April 12 /PRNewswire-Asia-FirstCall/ -- NeoStem, Inc. (NYSE Amex: NBS) ("NeoStem" or the "Company"), an international biopharmaceutical company with operations in the U.S. and China, announced the launch of the newest adult stem cell collection center in its network to open in Austin, ...
NeoStem's Suzhou Erye Pharmaceutical Subsidiary Receives Approval to Manufacture Generic Cloxacillin
NEW YORK, April 5 /PRNewswire-Asia-FirstCall/ -- NeoStem, Inc. ("NeoStem" or the "Company") (NYSE Amex: NBS), an international biopharmaceutical company with operations in the U.S. and China, announced that its Suzhou Erye Pharmaceutical subsidiary ("Erye") recently received approval from the Stat...
NeoStem Provides 2010 Business Outlook
NEW YORK, April 1 /PRNewswire-Asia-FirstCall/ -- NeoStem, Inc. (NYSE: NBS) ("NeoStem" or the "Company"), an international biopharmaceutical company with operations in the U.S. and China, today provided an update of its 2010 business outlook. "With the acquisition of a 51% interest in Suzh...
NeoStem Announces Warrant Exercise by Principal Shareholder
NEW YORK, March 18 /PRNewswire-Asia/ -- NeoStem, Inc. (NYSE: NBS) ("NeoStem" or the "Company"), an international biopharmaceutical company with operations in the U.S. and China, is pleased to announce the exercise of a warrant by a principal shareholder, RimAsia Capital Partners, LP ("RimAsia")....
NeoStem Appoints Deloitte & Touche as New Independent Registered Public Accounting Firm
NEW YORK, March 16 /PRNewswire-Asia/ -- NeoStem, Inc. (NYSE: NBS) ("NeoStem" or the "Company"), an international biopharmaceutical company with operations in the U.S. and China, announced today the appointment of Deloitte & Touche LLP ("Deloitte & Touche") as the Company's independent registered...
NeoStem Announces Presentation Time Change at Roth Capital Partners 22nd Annual OC Growth Stock Conference
NEW YORK, March 15 /PRNewswire-Asia/ -- NeoStem, Inc. (NYSE Amex: NBS) ("NeoStem" or the "Company"), an international biopharmaceutical company with operations in the U.S. and China, announced today a change for the Company's presentation at the Roth Capital Partners 22nd Annual OC Growth Stock ...
NeoStem to Present at ROTH Capital Partners 22nd Annual OC Growth Stock Conference
NEW YORK, March 9 /PRNewswire-Asia/ -- NeoStem, Inc. (NYSE: NBS) ("NeoStem" or the "Company"), an international biopharmaceutical company with operations in the U.S. and China, announced today that the Company will present at the upcoming ROTH Capital Partners 22nd Annual OC Growth Stock Confere...
NeoStem Enters into SRA with University of Michigan; Funding from NIH Stem Cell Research Grant
NEW YORK, March 4 /PRNewswire-Asia-FirstCall/ -- NeoStem, Inc. (NYSE Amex: NBS) ("NeoStem" or the "Company"), an international biopharmaceutical company with operations in the U.S. and China, announced today that it has entered into a sponsored research agreement (SRA) with the University of Mic...
Co-Founder of VSEL(TM) Technology Joins NeoStem's Scientific Advisory Board
NEW YORK, March 1 /PRNewswire-Asia/ -- NeoStem, Inc. (NYSE: NBS) ("NeoStem" or the "Company"), an international biopharmaceutical company with operations in the United States and China, announced today that it has appointed to its Scientific Advisory Board ("SAB") Mariusz Ratajczak, M.D., Ph.D.,...
NeoStem Closes 5,750,000 Share Public Offering
NEW YORK, Feb. 19 /PRNewswire-Asia-FirstCall/ -- NeoStem, Inc. (NYSE Amex: NBS) ("NeoStem" or the "Company"), an international biopharmaceutical company with operations in the U.S. and China, announced today the closing of its previously announced 5,000,000 share public offering and the exercise...
NeoStem Prices Public Offering of 5,000,000 Shares of Common Stock
NEW YORK, Feb. 12 /PRNewswire-Asia-FirstCall/ -- NeoStem, Inc. (NYSE Amex: NBS) ("NeoStem" or the "Company"), an international biopharmaceutical company with operations in the U.S. and China, announced today that it priced a public offering of 5,000,000 shares of its common stock at $1.35 per sh...
Busy Southwestern Orthopedic Practice Joins the NeoStem Stem Cell Collection Network
NEW YORK, Feb. 9 /PRNewswire-Asia/ -- NeoStem, Inc. (NYSE Amex: NBS) ("NeoStem" or the "Company"), an international biopharmaceutical company with operations in the U.S. and China, announced today that its stem cell collection network has expanded into the southwestern region of the U.S. with th...
NeoStem's Suzhou Erye Pharmaceutical Subsidiary Receives Approval for First Two Manufacturing Lines in its New Facility
NEW YORK, Feb. 1 /PRNewswire-Asia/ -- NeoStem, Inc. ("NeoStem" or the "Company") (NYSE Amex: NBS), an international biopharmaceutical company with operations in the U.S. and China, announced that it recently was advised that its Suzhou Erye Pharmaceutical subsidiary ("Erye") received approval fr...
NeoStem's Suzhou Erye Pharmaceutical Subsidiary Receives Approval to Manufacture Generic
NEW YORK, Jan. 25 /PRNewswire-Asia-FirstCall/ -- NeoStem, Inc. ("NeoStem" or the "Company") (NYSE Amex: NBS), an international biopharmaceutical company with operations in the U.S. and China, announced that it recently was advised that its Suzhou Erye Pharmaceutical subsidiary ("Erye") received ...
